Abstract
Objective: This study is to observe the therapeutic effects of Shenmai injection on patients with hypertensive ICH and cerebrocardiac syndromes as well as its effects on prognosis. Methods: A total of 72 patients with severe hypertensive ICH and cerebrocardiac syndromes were selected and divided into the control group and the experimental group (Shenmai injection group) randomly, 36 patients in each group. The control group was treated by conventional therapy, while the experimental group was administrated by intravenous drip of the mixture of 50 ml Shenmai injection and 250 ml 5% glucose injection based on the treatment of the control group, once everyday, 2 weeks continuously. Results: Myocardial enzyme indexes of two groups at 3d, 7d and 14d were observed (Table 1). Myocardial enzyme index of the experimental group was improved quickly and significantly. Myocardial enzyme data of two groups at 3d, 7d and 14d were P < 0.05. According to the electrocardiographic examinations results, ECG anomalies of the experimental group at 7d and 14d were also improved quickly (P < 0.05). There are no evident anomalies in GCS scores of two groups at 7d, but GCS score of the experimental group at 14d of the medication was significantly higher than that of the control group (P < 0.05). Conclusions: Shenmai injection has some therapeutic effects on cerebral injuries and myocardial damages. It can treat brain and heart simultaneously, realize the goal of addressing both symptoms and root causes, and improve prognosis of patients with severe hypertensive ICH.
Highlights
Intracerebral hemorrhage (ICH) can threaten life and physical health of the aged group seriously due to its high morbidity, high fatality rate and high disability rate in clinics
The control group was treated by conventional therapy, while the experimental group was administrated by intravenous drip of the mixture of 50 ml Shenmai injection and 250 ml 5% glucose injection based on the treatment of the control group, once everyday, 2 weeks continuously
There are no evident anomalies in GCS scores of two groups at 7d, but GCS score of the experimental group at 14d of the medication was significantly higher than that of the control group (P < 0.05)
Summary
Intracerebral hemorrhage (ICH) can threaten life and physical health of the aged group seriously due to its high morbidity, high fatality rate and high disability rate in clinics. Cerebrocardiac syndromes are clinical syndromes which are developed upon cardiac dysfunction or myocardial disorder caused by serious diseases of central nervous system, and they are called brain-derived cardiovascular dysfunction. Few studies on the combination of severe hypertensive ICH and cerebrocardiac syndromes have been reported in China. It has not attracted enough attentions in clinics, accompanied with high rate of missed diagnosis and misdiagnosis rate. Most antiarrhythmic drugs have poor therapeutic effects to cerebrocardiac syndromes. It is difficult to treat cerebrocardiac syndromes. Based on conventional western drug therapy, our hospital applies Shenmai injection to treat patients with severe hypertensive ICH and cerebrocardiac syndromes, which has achieved outstanding therapeutic effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have